See more : Hong Leong Bank Berhad (5819.KL) Income Statement Analysis – Financial Results
Complete financial analysis of HYUGA PRIMARY CARE Co.,Ltd. (7133.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HYUGA PRIMARY CARE Co.,Ltd., a leading company in the Healthcare industry within the Healthcare sector.
- Gladstone Investment Corporation 5.00% Notes Due 2026 (GAINN) Income Statement Analysis – Financial Results
- Northern Star Investment Corp. II (NSTB-UN) Income Statement Analysis – Financial Results
- Britannia Industries Limited (BRITANNIA.BO) Income Statement Analysis – Financial Results
- HY Energy Group Co.,Ltd (600387.SS) Income Statement Analysis – Financial Results
- Ardoin ST Amand A (MLARD.PA) Income Statement Analysis – Financial Results
HYUGA PRIMARY CARE Co.,Ltd. (7133.T)
About HYUGA PRIMARY CARE Co.,Ltd.
HYUGA PRIMARY CARE Co.,Ltd. provides home-visit pharmacies, nursing, and care planning services in Japan. The company offers know-how, systems, human resources, and sales for home visiting pharmacy operations to small and medium-sized pharmacy operators; lends Fam Care, an home visit support information system; On-call system support; and guidance on home palliative care. It also provides Tai Support, a nursing facility search site that offers medical social workers with information on senior housing with services, paid nursing homes, group homes, etc.; Mimamori ICT Robot Terminal, a wearable device for nursing care facilities; operates a home visiting pharmacy that delivers prescription drugs directly to patients; and engages in the primary care home business. The company was formerly known as Hyuga Pharmacy Co., Ltd. and changed its name to HYUGA PRIMARY CARE Co.,Ltd. in October 2020. HYUGA PRIMARY CARE Co.,Ltd. was incorporated in 2007 and is based in Kasuga, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 8.29B | 6.66B | 5.78B | 5.09B | 4.33B |
| Cost of Revenue | 6.40B | 5.09B | 4.55B | 4.30B | 3.77B |
| Gross Profit | 1.88B | 1.56B | 1.24B | 783.83M | 559.00M |
| Gross Profit Ratio | 22.71% | 23.47% | 21.37% | 15.41% | 12.91% |
| Research & Development | 0.00 | 0.00 | 0.00 | 9.75M | 0.00 |
| General & Administrative | 0.00 | 93.00M | 70.00M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 924.00M | 629.00M | 0.00 | 0.00 |
| SG&A | 1.17B | 1.02B | 699.00M | 555.00M | 436.00M |
| Other Expenses | 0.00 | 29.48M | -10.36M | 25.77M | 0.00 |
| Operating Expenses | 1.17B | 1.03B | 716.83M | 555.63M | 496.00M |
| Cost & Expenses | 7.58B | 6.13B | 5.26B | 4.86B | 4.27B |
| Interest Income | 1.98M | 7.00K | 5.00K | 95.00K | 92.00K |
| Interest Expense | 9.74M | 2.03M | 2.57M | 3.35M | 2.73M |
| Depreciation & Amortization | 189.80M | 91.19M | 78.86M | 90.51M | -123.00M |
| EBITDA | 854.38M | 627.27M | 587.61M | 258.55M | 0.00 |
| EBITDA Ratio | 10.31% | 9.78% | 10.16% | 6.78% | -1.43% |
| Operating Income | 710.68M | 530.30M | 519.11M | 228.20M | 123.00M |
| Operating Income Ratio | 8.58% | 7.97% | 8.98% | 4.49% | 2.84% |
| Total Other Income/Expenses | -55.84M | 3.75M | -31.85M | -63.52M | -62.00M |
| Income Before Tax | 654.84M | 534.05M | 487.26M | 164.68M | 61.00M |
| Income Before Tax Ratio | 7.90% | 8.02% | 8.43% | 3.24% | 1.41% |
| Income Tax Expense | 213.81M | 151.17M | 158.80M | 67.54M | 29.00M |
| Net Income | 441.03M | 382.88M | 328.45M | 97.14M | 32.00M |
| Net Income Ratio | 5.32% | 5.75% | 5.68% | 1.91% | 0.74% |
| EPS | 62.05 | 53.92 | 47.90 | 14.50 | 4.62 |
| EPS Diluted | 59.26 | 50.82 | 43.32 | 14.50 | 4.62 |
| Weighted Avg Shares Out | 7.11M | 7.10M | 6.86M | 6.70M | 6.92M |
| Weighted Avg Shares Out (Dil) | 7.44M | 7.53M | 7.58M | 6.70M | 6.92M |
Source: https://incomestatements.info
Category: Stock Reports